Eli Lilly and Company (LLY)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
WOK
WORK Medical Technology Group LTD Ordinary Shares
$1.88
-2.59%
HEALTHCARE · Cap: $9.38M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 743199% more annual revenue ($79.67B vs $10.72M). LLY leads profitability with a 33.5% profit margin vs -41.9%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
WOK
Avoid35
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
19.1% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -5.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : WOK
The strongest argument for WOK centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 19.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : WOK
The primary concerns for WOK are Altman Z-Score, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
WOK carries more volatility with a beta of 1.75 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 35/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →WORK Medical Technology Group LTD Ordinary Shares
HEALTHCARE · MEDICAL DEVICES · USA
WORK Medical Technology Group Ltd is a pioneering player in the medical technology sector, dedicated to the advancement of healthcare through the research, development, and commercialization of innovative medical devices. The company's diverse portfolio is designed to tackle pressing challenges in global healthcare, underscoring its commitment to improving patient outcomes. With a strong emphasis on quality, innovation, and responsiveness to market demands, WORK is ideally positioned for sustainable growth, making it an attractive investment opportunity for institutional investors seeking exposure to transformational healthcare solutions in an evolving industry landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?